Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Item 5.02(d)
On June 21, 2021, the Board of Directors (the "Board") of Inari Medical, Inc., a
Delaware corporation (the "Company") determined to increase the size of the
Board from six (6) directors to seven (7) directors and appointed Rebecca
Chambers as a new member of the Board and as a member of the Audit Committee of
the Board, with such appointment to be effective immediately. Mr. Nielsen will
no longer serve on the Audit Committee effective as of the date of Ms. Chambers'
appointment. Ms. Chambers' term of office as a Class I Director will expire at
the Company's 2024 annual meeting of stockholders or until her successor has
been elected and qualified or her earlier death, resignation or removal. The
Board has determined that Ms. Chambers is an "independent director" as defined
under the applicable rules and regulations of the Securities and Exchange
Commission (the "SEC") and the listing requirements and rules of the Nasdaq
stock market.
Since June 2019, Ms. Chambers has served as the Chief Financial Officer of
Outset Medical, Inc., a NASDAQ listed medical technology company pioneering a
novel technology to reduce the cost and complexity of dialysis. Prior to that,
she was at Illumina, a NASDAQ listed genetic tools company, where she served in
a number of roles: as the Vice President, Financial Planning and Analysis from
July 2017 to May 2019, as Vice President, Investor Relations and Treasury from
April 2015 to June 2017, and as Senior Director, Investor Relations from October
2012 to April 2015. Previously, Ms. Chambers served as Head of Investor
Relations and Corporate Communications at Myriad Genetics, a NASDAQ listed
molecular diagnostic company, from January 2011 to October 2012, and in various
roles in investor relations at Life Technologies, a biotechnology company, from
May 2009 to December 2010. She also previously held positions with Bank of
America, a financial services company, and Millennium Pharmaceuticals, a
biopharmaceutical company that was acquired by Takeda Pharmaceuticals Co. Ms.
Chambers holds a B.S. from John Carroll University and an M.B.A. from The S.C.
Johnson Graduate School of Management, Cornell University.
Ms. Chambers will be compensated in a manner consistent with the Company's other
non-employee directors, as described under the heading "Director Compensation"
in the Company's definitive proxy statement filed with the SEC on April 16,
2021.
There are no arrangements or understandings between Ms. Chambers and any other
persons pursuant to which she was appointed as a director. Furthermore, there
are no transactions in which Ms. Chambers has an interest that would be required
to be reported under Item 404(a) of Regulation S-K.
Item 7.01. Regulation FD Disclosure.
On June 21, 2021, the Company issued a press release announcing the appointment
of Ms. Chambers. A copy of the press release is attached hereto as Exhibit
99.1.
The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act"), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference into any other
filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release dated June 22, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
INARI MEDICAL, INC. 
